~~<i id='3C3F86563F'><strike id='3C3F86563F'><tt id='3C3F86563F'><pre id='3C3F86563F'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：focus 2025-08-24 23:08:27 Page View：72562

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Timeline: How the deadly wildfires took over Maui day by day
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Search called off for baby washed away in Pennsylvania flash flood

1:30UpperMakefieldTownshipPoliceDepartmentreleasedthisphotoofKatieSeley,a32-year-oldmotherofthreewho

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Biogen’s boardroom scandal saddles CEO with first crisis

ChrisViehbachertookoverasBiogenCEOinNovember.SuzanneKreiter/Globestaff;PhotoillustrationAlexHogan/ST